Indications
Neoceptin R is indicated for the treatment of duodenal ulcer, benign gastric ulcer, post-operative
ulcer, oesophageal reflux disease and Zollinger-Ellison Syndrome. It is also indicated in the
conditions where reduction of gastric secretion and acid output is desirable e.g. the prophylaxis
of gastrointestinal haemorrhage from stress ulceration in seriously ill patients, the prophylaxis of
recurrent haemorrhage in patients with bleeding peptic ulcers. Neoceptin R is indicated before
general anaesthesia in patients considered to be at risk of acid aspiration (Mendelson’s
Syndrome) particularly obstetric patients during labour.
Dosage and Administration
The usual adult dose of Neoceptin R is 100ml containing 50mg Ranitidine which is to be
administered 6 to 8 hourly over a period of 15 to 20 minutes at a rate of 5 to 7 ml per minute. In
some patients, it may be necessary to increase the dose but the total daily dose of Neoceptin R
should not exceed 400mg. For patients with renal impairment, dosage interval should be 18 to
24 hours. In the prophylaxis of haemorrhage from stress ulceration and peptic ulceration,
parenteral administration may be continued until oral feeding commences. Neoceptin R may be
given 45 to 60 minutes before induction of general anaesthesia to patients considered to be at
risk of developing acid aspiration syndrome.
Contraindications
Neoceptin R is contraindicated for patients known to have hypersensitivity to this drug.
Precautions
Treatment with Neoceptin R may mask the symptoms associated with carcinoma of stomach
and may therefore delay the diagnosis of the condition. Since Neoceptin R is excreted primarily
by kidney, dosage should be adjusted in patients with impaired renal function. Similar caution
should also be taken for patients with hepatic dysfunction. Rare reports suggest that Neoceptin
R may precipitate acute porphyria attacks in patients with acute porphyria. Neoceptin R
therefore should be avoided in patients with history of acute porphyria.
Use in Pregnancy & Lactation
Studies in rats and rabbits at an oral dose up to 160 times of human oral dose have revealed no
evidence of harm to the fetus or fertility due to ranitidine. Ranitidine is secreted in human milk.
Caution should be taken when it is given to lactating mothers.
Reviews
There are no reviews yet.